Ποια είναι η τιμή για MGC Pharmaceuticals Limited (MXC)

Η τιμή για MGC Pharmaceuticals Limited (MXC) είναι $0.27239819

Ποια είναι η κεφαλαιοποίηση αγοράς για MGC Pharmaceuticals Limited (MXC)

Η κεφαλαιοποίηση αγοράς για MGC Pharmaceuticals Limited (MXC) είναι $330.42K

MGC Pharmaceuticals Limited (MXC) Τιμή και Κεφαλαιοποίηση Αγοράς

MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established in West Perth in 2014, focuses on the worldwide development and distribution of plant-derived medicines. Its product portfolio encompasses both medicinal cannabis solutions and other botanical therapeutics. The company's key investigational treatments include CimetrA, currently in Phase III clinical trials for the symptomatic relief of early-stage COVID-19; CannEpil, a cannabis-based therapy undergoing Phase IIb studies for drug-resistant epilepsy; and CogniCann, which is in Phase II clinical development for alleviating dementia symptoms. Beyond these core candidates, MGC Pharmaceuticals also supplies the ArtemiC range, various other cannabinoid-infused products, and non-pharmaceutical items. Additionally, the company provides expert consulting services, particularly in clinical research. The company was previously named Erin Resources Limited before adopting its current identity, MGC Pharmaceuticals Limited, in December 2015.

Η τιμή για MXC	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$4,509,100 $330.42K	NVDA	$5.470T	+1,655,333,783.30%
$3,682,664 $330.42K	AAPL	$4.467T	+1,351,941,256.29%
$3,441,374 $330.42K	GOOG	$4.174T	+1,263,361,352.97%
$3,050,352 $330.42K	MSFT	$3.700T	+1,119,813,600.87%
$2,353,127 $330.42K	AMZN	$2.854T	+863,855,380.45%

Η τιμή για MXC

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$4,509,100 $330.42K